Limits...
Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study.

Osborne RH, Dalton A, Hertel J, Schrover R, Smith DK - Health Qual Life Outcomes (2012)

Bottom Line: Ninety-eight people completed the TTO interview.The vignettes were presented in random order to prevent possible ordering effects.The treated health states were rated at much higher utilities and were statistically significantly different (p < 0.001) from each other: (1) 2-weekly: mean (median) utility = 0.61 (0.65); (2) 4-weekly: mean (median) utility = 0.65 (0.70); (3) 3-monthly: mean (median) utility = 0.70 (0.75).

View Article: PubMed Central - HTML - PubMed

Affiliation: Public Health Innovation, Population Health Strategic Research Centre, Deakin University, 221 Burwood Highway, Burwood, VIC, Australia. richard.osborne@deakin.edu.au

ABSTRACT

Background: This study was undertaken to estimate utility values for alternative treatment intervals for long acting antipsychotic intramuscular injections for the treatment of schizophrenia.

Methods: Vignettes were developed using the published literature and an iterative consultation process with expert clinicians and patient representative groups. Four vignettes were developed. The first was a vignette of relapsed/untreated schizophrenia. The other three vignettes presented a standardised picture of well-managed schizophrenia with variations in the intervals between injections: once every 2-weeks, 4-weeks and 3-months. A standardised time trade off (TTO) approach was used to obtain utility values for the vignettes. As a societal perspective was sought, a representative sample of individuals from across the community (Sydney, Australia) was recruited. Ninety-eight people completed the TTO interview. The vignettes were presented in random order to prevent possible ordering effects.

Results: A clear pattern of increasing utility was observed with increasing time between injections. Untreated schizophrenia was rated as very poor health-related quality of life with a mean (median) utility of 0.27 (0.20). The treated health states were rated at much higher utilities and were statistically significantly different (p < 0.001) from each other: (1) 2-weekly: mean (median) utility = 0.61 (0.65); (2) 4-weekly: mean (median) utility = 0.65 (0.70); (3) 3-monthly: mean (median) utility = 0.70 (0.75).

Conclusions: This study has provided robust data indicating that approximately a 0.05 utility difference exists between treatment options, with the highest utility assigned to 3-monthly injections.

Show MeSH

Related in: MedlinePlus

Vignettes used in time trade off interviews.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3369822&req=5

Figure 1: Vignettes used in time trade off interviews.

Mentions: At interview, each participant was presented with standardized background information on schizophrenia and its treatment, together with short descriptions (vignettes or scenarios) of three health states for people with schizophrenia. These vignettes were designed to be clinically and domestically realistic, and easily understood. Each of the vignettes is presented in Figure 1, and can be summarized as follows: (1) a background health state of untreated schizophrenia, (2) treated schizophrenia with injections once every 2 weeks, (3) treated schizophrenia with injections once every 4 weeks, and (4) treated schizophrenia with injections once every 3 months.


Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study.

Osborne RH, Dalton A, Hertel J, Schrover R, Smith DK - Health Qual Life Outcomes (2012)

Vignettes used in time trade off interviews.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3369822&req=5

Figure 1: Vignettes used in time trade off interviews.
Mentions: At interview, each participant was presented with standardized background information on schizophrenia and its treatment, together with short descriptions (vignettes or scenarios) of three health states for people with schizophrenia. These vignettes were designed to be clinically and domestically realistic, and easily understood. Each of the vignettes is presented in Figure 1, and can be summarized as follows: (1) a background health state of untreated schizophrenia, (2) treated schizophrenia with injections once every 2 weeks, (3) treated schizophrenia with injections once every 4 weeks, and (4) treated schizophrenia with injections once every 3 months.

Bottom Line: Ninety-eight people completed the TTO interview.The vignettes were presented in random order to prevent possible ordering effects.The treated health states were rated at much higher utilities and were statistically significantly different (p < 0.001) from each other: (1) 2-weekly: mean (median) utility = 0.61 (0.65); (2) 4-weekly: mean (median) utility = 0.65 (0.70); (3) 3-monthly: mean (median) utility = 0.70 (0.75).

View Article: PubMed Central - HTML - PubMed

Affiliation: Public Health Innovation, Population Health Strategic Research Centre, Deakin University, 221 Burwood Highway, Burwood, VIC, Australia. richard.osborne@deakin.edu.au

ABSTRACT

Background: This study was undertaken to estimate utility values for alternative treatment intervals for long acting antipsychotic intramuscular injections for the treatment of schizophrenia.

Methods: Vignettes were developed using the published literature and an iterative consultation process with expert clinicians and patient representative groups. Four vignettes were developed. The first was a vignette of relapsed/untreated schizophrenia. The other three vignettes presented a standardised picture of well-managed schizophrenia with variations in the intervals between injections: once every 2-weeks, 4-weeks and 3-months. A standardised time trade off (TTO) approach was used to obtain utility values for the vignettes. As a societal perspective was sought, a representative sample of individuals from across the community (Sydney, Australia) was recruited. Ninety-eight people completed the TTO interview. The vignettes were presented in random order to prevent possible ordering effects.

Results: A clear pattern of increasing utility was observed with increasing time between injections. Untreated schizophrenia was rated as very poor health-related quality of life with a mean (median) utility of 0.27 (0.20). The treated health states were rated at much higher utilities and were statistically significantly different (p < 0.001) from each other: (1) 2-weekly: mean (median) utility = 0.61 (0.65); (2) 4-weekly: mean (median) utility = 0.65 (0.70); (3) 3-monthly: mean (median) utility = 0.70 (0.75).

Conclusions: This study has provided robust data indicating that approximately a 0.05 utility difference exists between treatment options, with the highest utility assigned to 3-monthly injections.

Show MeSH
Related in: MedlinePlus